Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yasmeen Kabir

Hospitalist West Hollywood, CA Medical Doctor

NPI 1043530181 CMS profile 1301163

8700 Beverly Blvd, West Hollywood, CA 90048

Open in the dashboard

General payments

$4,136

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yasmeen Kabir of West Hollywood, CA is reported in the CMS Open Payments database as having received $4,136 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $464 9
2024 General $99 4
2023 General $537 9
2022 General $944 15
2021 General $745 31
2020 General $618 13
2019 General $729 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yasmeen Kabir
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Yasmeen Kabir were reported at $464. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Yasmeen Kabir Hospitalist median Middle half National median
2019 $729 $96 $28–$201 $163
2020 $618 $48 $19–$125 $114
2021 $745 $70 $23–$167 $132
2022 $944 $85 $27–$174 $149
2023 $537 $89 $30–$191 $160
2024 $99 $95 $29–$204 $164
2025 $464 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,442 19 payments
  2. AbbVie, Inc. $430 15 payments
  3. Janssen Biotech, Inc. $365 24 payments
  4. Organogenesis Inc. $155 2 payments
  5. Novartis Pharmaceuticals Corporation $146 7 payments
  6. Galderma Laboratories, L.P. $139 8 payments
  7. Sun Pharmaceutical Industries Inc. $94 4 payments
  8. Regeneron Healthcare Solutions, Inc. $76 2 payments
  9. Lilly USA, LLC $70 4 payments
  10. Genzyme Corporation $68 3 payments
  11. Other $151 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,036 94 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. Xience V coronary stent system $792 8 payments
  2. DRAGONFLY OPSTAR $543 3 payments
  3. SIMPONI $265 23 payments
  4. SIMPONI ARIA $265 23 payments
  5. STELARA $265 23 payments
  6. REMICADE $265 23 payments
  7. PRESSUREWIRE $213 2 payments
  8. XIENCE SKYPOINT $189 1 payment
  9. HUMIRA $188 4 payments
  10. Perclose ProStyle $179 1 payment
  11. Other $1,701 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

393

Median for Hospitalist: 109

Drug cost

$9,073

Median for Hospitalist: $6,399

Branded share of claims

0%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 91 $3,659
Tacrolimus Generic 15 $1,016
Clobetasol Propionate Generic 41 $957
Ketoconazole Generic 65 $838
Triamcinolone Acetonide Generic 69 $673
Econazole Nitrate Generic 20 $464
Fluocinolone Acetonide Generic 15 $406
Clindamycin Phosphate Generic 20 $368
Doxycycline Monohydrate Generic 16 $294
Hydrocortisone Generic 21 $222

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $46
$46 — —
DUPIXENT
  • GENZYME CORPORATION $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record